Securities code: 000503 securities abbreviation: China Reform Health Management And Services Group Co.Ltd(000503) China Reform Health Management And Services Group Co.Ltd(000503)
Record of investor relations activities
No.: 2021-04
□ specific object research □ analyst meeting
Investor relations
□ media interview □ performance briefing
Activity category
□ press conference √ Roadshow
□ site visit □ others ()
Securities Wang Zai Cun Ying Ying Yang Ming Chun Wu Yan
Huaxia Fund Wang Zeshi
Ma MuQing of CCB fund
Ruan Xinyi of Agricultural Bank of China
Name of participant and Hua’an Asset Management Co., Ltd
Personnel name: Lingren investment He Xin
Taikang assets Wang Yuxing
Dai Fuhong, Chinese business fund
Great Wall Fund long Yufei
Harvest Fund Cheng Jia
Time: 12:00-13:00, December 24, 2021
Location: Fengrong international building, Xicheng District, Beijing
Receptionist of listed company: Liu Xinxing, Secretary of the board of directors of the company
Member name: Zhang Zhenhua, member of the Party committee of the company and general manager of Medical Insurance Division
1、 Company profile
China Reform Health Management And Services Group Co.Ltd(000503) (hereinafter referred to as ” China Reform Health Management And Services Group Co.Ltd(000503) ” or “referendum investor relationship activity Department”) is a listed company of central enterprises controlled by China Guoxin. It takes building “China’s leading builder of health security service system” as its corporate vision, and realizes the corporate mission of “introducing health security services with fair and just main contents for everyone”. The company takes “one body and two wings” As the framework, it serves China’s health security service system, focuses on the three business directions of “comprehensive management service of medical insurance fund, medical quality and safety service and pharmaceutical machinery supervision service”, provides technical support services such as informatization and big data application for the national strategy of “healthy China”, and supports the reform of “three medical linkage”. at present
Its business covers 26 provincial administrative units and more than 190 medical insurance overall planning areas. 2、 Investors’ questions and exchanges 1. Recently, the National Medical Security Bureau issued a notice on the three-year action plan for DRG / Dip payment method reform. What is the progress of DRG / Dip nationwide and the company’s business? In addition to DRG and dip business, what are the company’s business layouts at the medical insurance end? A: before the issuance of the three-year action plan for DRG / Dip payment reform by the National Medical Security Bureau, DRG or dip system construction has been supported in many regions throughout the country. In some places, DRG / dip and other payment methods coexist. From the perspective of system construction, the early investment cost of DRG is higher; In the operation and maintenance stage, the expenses in different regions are different according to regional needs and policies. The company’s medical insurance business not only provides payment method reform services, but also includes intelligent audit services, credit evaluation services and other work. It is a solution for the integration of medical insurance. With the payment method as the starting point to promote the business, the income may be greater in the future. The plan released by the national medical insurance bureau is to promote the reform of payment method. It is expected that in 2022, in addition to the existing pilot cities, about 80% to 90% of prefectures and cities will start the work related to the reform of payment method. From the perspective of provincial level platform construction, the company has carried out corresponding work in more than ten provinces. 2. What services does the company’s digital medical business specifically include? Will the DRG / Dip payment method reform also promote the company’s business layout at the hospital end? A: the company’s digital medical business mainly includes two aspects. On the one hand, it provides regional medical service quality supervision services for local health authorities. It can be summarized as “one platform, two systems and three levels”, and one platform is the intelligent supervision platform of regional medical services; The two systems refer to the medical service supervision system of the competent health department and the intelligent monitoring system of medical institutions; The three levels refer to the three levels of “province city county”. Finally, it can effectively restrict the unreasonable medical service behavior of doctors, effectively evaluate the service quality of hospitals, professional departments and clinicians in the region, assist the competent health departments and medical institution management departments to make scientific decisions, and promote the improvement of regional medical service quality.
On the other hand, it is aimed at the hospital big data medical operation control service provided by medical institutions. The hospital big data medical operation control service system is the pain point and actual demand of the company based on many years of professional service experience in medical insurance management, combined with hospital, medical insurance, medical service and operation management, A set of information support system for hospital users to optimize hospital revenue, cost and performance under the condition of compound payment reform policy. Through the use and supporting services of the system in the hospital, it can effectively improve the data quality of the first page of medical records, carry out real-time and dynamic grouping early warning, and provide decision support for the fine management of the hospital under the DRG / Dip reform. Based on its rich experience in payment reform, the company further extends its service capacity to disease group cost accounting and performance appraisal of public hospitals, so as to help hospitals reasonably optimize medical costs and obtain good economic and social benefits on the premise of ensuring medical quality. With DRG / Dip payer
With the development and deepening of the reform, medical institutions, as the provider of medical services, are bound to extend to the level of medical institutions. At present, most medical institutions are actively complying with the reform trend of DRG / Dip payment mode, taking advantage of the trend and actively strengthening internal fine management. At present, the company has covered more than 600 medical institutions. The reform of DRG / Dip payment method will further promote the company’s business layout at the hospital end. 3. What is the difference between DRG and dip systems? A: both are the concept of payment method. The former is widely implemented in the world and has high professional requirements, especially involving grouping. On the whole, the requirements for basic conditions are relatively high, but the level of informatization in China is uneven, so we can’t copy the international situation. In terms of dip, many years ago, some regions tried to pay by disease score, and more measured historical data from a statistical point of view. The operation is not necessarily simple, but it will be relatively easy to understand. In addition, DRG is more from a clinical perspective, and dip is more based on historical data for payment management. The thinking logic of the two is also different. From the perspective of system construction, they also belong to two sets of systems and pay attention to different indicators. 4. How to understand DRG / Dip business and what are the advantages of the company? A: DRG / dip is not a simple information construction project, but a multi-disciplinary and comprehensive service, including medical insurance end and hospital end. It is an interdisciplinary integration process from various aspects such as system transformation, medical record information filling and personnel training, and requires a large number of talents. From a multidisciplinary perspective, there will be a lot of operation and maintenance work in the future, because the payment method is not invariable and requires the participation of a professional third party such as the company. This is a comprehensive work with continuity. Since the DRG / Dip payment method reform is a project led by the National Medical Insurance Bureau, led by Prefecture and municipal governments and mainly built by provincial and municipal medical insurance bureaus, the medical insurance end is mostly funded by local governments, with large investment, and the construction funds are mostly earmarked for special purposes; In order to quickly comply with the reform of DRG / Dip payment mode, medical institutions must also strengthen internal management and control in terms of data quality, medical quality, cost control, fund supervision and internal performance evaluation. Most hospital end projects are self funded by the hospital, which also has strong guarantee in terms of investment.
The company is a professional company in the DRG / Dip field. At present, there are roughly three types of participants in this field in the market: insurance companies, information companies and professional service companies. The company is relatively objective and neutral. Among the professional technicians in the team, there are more professionals in medicine, pharmacy, statistics and medical records, and the angles and methods of dealing with problems are also different. The company is committed to becoming a comprehensive service provider, using clinical, pharmaceutical, statistical and other knowledge to provide professional comprehensive services. 5. What are the revenue segments of the company’s three business segments: digital medical insurance, digital medical care and digital medicine? A: according to the composition of operating income disclosed in the company’s 2020 annual report, the income of digital medical insurance business is 112852586.08 yuan, accounting for 54.42%; The revenue of digital medicine business was 54939372.84 yuan, accounting for 26.49%; The revenue of digital medical business was 39436451.98 yuan, accounting for 19.02%.
6. It can be seen from the equity incentive plan released by the company that the company is full of confidence in its future development prospects. What are the considerations for the company to set higher performance unlocking conditions? A: the company has always adhered to the overall leadership of the party, continuously improved its strategic management ability and optimized the company’s organizational structure. In the next few years, China Reform Health Management And Services Group Co.Ltd(000503) will continue to maintain its strategic positioning and resolutely implement the strategic path of medical insurance card, medical income increase and medical support. On the basis of doing a good job in the medical insurance end card position and steadily promoting the expansion of medical insurance informatization business, do a good job in the following two aspects:
First, closely follow the implementation progress of DRG and dip at the Bureau end, prospectively layout hospital operation management services, and strive to develop core products such as DRG / Dip intelligent management, medical record management and performance appraisal to meet the new needs of customers. Taking the large regional or provincial market as the unit, based on the card position of the medical insurance end, cooperate with the online time rhythm of DRG, focus on the core hospital, create a regional benchmark, realize the rapid replication from 1 to N, and strive to achieve a scale breakthrough at the hospital end.
Second, further focus on to B and to C customers, give full play to the advantages of Guoxin’s link to central enterprise resources, and create conditions and provide scenes and resources for the company to pilot the health management business model in specific regions through resource integration between central enterprises. Continue to explore such businesses as prescription circulation, direct compensation and quick compensation, and people-friendly insurance. 7. What is the impact of payment reform on the income of medical institutions? A: the impact of this aspect mainly depends on the hospital’s medical service capacity, the number of patients and the level of internal management. In the past, the total hospitalization expenses control scheme under the total budget determined the annual limit of medical insurance hospitalization expenses of each medical institution. This method lacks data support, scientific decision-making basis and objective human factors. The DRG / Dip payment standard is determined based on the three-year historical data of all pilot medical institutions in the city, combined with scientific data calculation methods, which is highly objective and scientific. In DRG / Dip payment mode, Medical institutions’ access to medical insurance fund mainly depends on DRG / Dip disease group (species), number of patients and payment coefficient. 8. Seeing that the company is also strengthening its layout in foreign investment this year and has participated in the equity of Yiyong technology and other companies, what is the purpose of the company’s foreign investment? A: the company actively implements “one body, two wings, two wheel drive, digital empowerment and healthy ecology” Strategic planning, relying on the two wheel drive of industrial operation and capital operation, actively carry out investment cooperation and cultivate the health care big data industry ecosystem. For example, Yiyong technology is a technology enterprise that carries out business around the tumor big data ecosystem. The company assisted relevant national units in building the tumor big database, accumulated the data processing capacity of tumor data collection, quality control and governance, and provided technical support for tumor big data analysis and mining. Yiyong technology continues to explore the business path, extend the central business to the hospital business, and develop hospital-side products such as data governance platform, clinical scientific research integration platform and hospital-side single disease germplasm control platform. In the future, it plans to provide comprehensive services for tumor patients to meet the actual needs of tumor patients in disease diagnosis and treatment. Based on the prospect of the future commercialization of the hospital business model and the complementarity between China Reform Health Management And Services Group Co.Ltd(000503) and China Reform Health Management And Services Group Co.Ltd(000503) in terms of data, platform and resources, after the completion of the transaction, both parties will
The efficiency of resource operation will be improved, the core competitiveness will be effectively utilized and expanded, which may have a positive impact on the company’s financial situation and conform to the company’s future development direction and strategic positioning. In the process of communication with investors, the management of the company strictly follows the management measures for information disclosure and other provisions to ensure the authenticity, accuracy, integrity, timeliness and fairness of information disclosure. There is no disclosure of undisclosed major information. Meanwhile, the letter of commitment for research has been signed as required by Shenzhen Stock Exchange.
Annex list (if any) none
Date: December 24, 2021
